Neutrons reveal unpredicted binding between SARS-CoV-2, hepatitis C antiviral drug

Researchers used neutron scattering to investigate the interactions between telaprevir, a drug used to treat hepatitis C viral infection, and the SARS-CoV-2 main protease, the enzyme responsible for enabling the virus to reproduce. Unforeseen changes in the electric charges were discovered in the drug binding site of the protease enzyme that were not predicted by prevailing computer simulations. The research provides key insights for advancing drug design and drug repurposing efforts to treat COVID-19. View original article here Source

Related Posts